Ruxolitinib treatment in myelofibrosis and polycythemia vera causes suboptimal humoral immune response following standard and booster vaccination with BNT162b2 mRNA COVID-19 vaccine

• DOI: 10.3389/fonc.2023.1117815
• Publication Date: 2023-02-14T18:36:26Z
• Authors: Giuseppe A. Palumbo; Daniela Cambria; Enrico La Spina; Andrea Duminuco; Antonio Laneri; Anna Longo; Calogero Vetro; Sebastiano Giallongo; Alessandra Romano; Francesco Di Raim...; Daniele Tibullo; Cesarina Giallongo
• Keywords: Ruxolitinib; Booster dose; Antibody response; Booster (rocketry)

Patients affected by myelofibrosis (MF) or polycythemia vera (PV) and treated with ruxolitinib are at high risk for severe coronavirus disease 2019. Now a vaccine against the virus SARS-CoV-2, which is responsible this disease, available. However, sensitivity to vaccines usually lower in these patients. Moreover, fragile patients were not included large trials investigating efficacy of vaccines. Thus, little known about approach group In prospective single-center study, we evaluated 43 (30 MF 13 PV) receiving as treatment their myeloproliferative disease. We measured anti-spike anti-nucleocapsid IgG SARS-CoV2 15-30 days after second third BNT162b2 mRNA booster dose. showed an impaired antibody response complete vaccination (2 doses), 32.5% did develop any response. After dose Comirnaty, results slightly improved, 80% produced antibodies above threshold positivity. quantity was well below that reached than those reported healthy individuals. PV elicited better MF. different strategies should be considered high-risk